Organon & Co is a global healthcare company focused on women's health, biosimilars, and established medicines. Its core products include contraceptives, hormone therapies, and treatments for various chronic conditions. The company operates primarily in women's health and biosimilars, with major revenue sources stemming from its portfolio of prescription medications and healthcare solutions. Organon aims to address unmet medical needs and improve health outcomes for women.
The investment profile of Organon & Co is more aligned with balanced investors, given its modest dividend yield and stable revenue streams. The company has shown some volatility and a recent decline in revenue, which may appeal to those seeking a mix of growth and income. The stock's characteristics suggest it may be suitable for investors looking for moderate risk and potential for steady returns over time.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-05 02:45 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-28 02:54 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:33 | — | Hold | Weak fundamentals and high volatility raise concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-04-27 20:27 | Piper Sandler | Rating Upgraded | — → 14 | 13.175 |
| 2026-04-10 15:02 | BNP Paribas | Update | — → 12 | 8.685 |
| 2026-02-24 10:45 | Barclays | Target Raised | 7.5 → 8 | 7.92 |
